IDEXX Laboratories (NASDAQ:IDXX) Price Target Cut to $596.00

IDEXX Laboratories (NASDAQ:IDXX) had its price target reduced by Morgan Stanley from $620.00 to $596.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have an overweight rating on the stock.

A number of other analysts have also recently issued reports on IDXX. The Goldman Sachs Group increased their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a buy rating in a research note on Wednesday, January 17th. Barclays lowered their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an overweight rating on the stock in a research report on Thursday, May 2nd. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an overweight rating in a research report on Tuesday, February 6th. William Blair reissued an outperform rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Finally, StockNews.com lowered shares of IDEXX Laboratories from a buy rating to a hold rating in a report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of Moderate Buy and an average price target of $580.38.

IDEXX Laboratories Stock Up 0.5 %

NASDAQ IDXX opened at $543.45 on Tuesday. IDEXX Laboratories has a 52 week low of $372.50 and a 52 week high of $583.39. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $44.88 billion, a P/E ratio of 52.61, a price-to-earnings-growth ratio of 4.32 and a beta of 1.27. The stock’s 50-day moving average price is $511.99 and its 200-day moving average price is $518.99.

Institutional Investors Weigh In On IDEXX Laboratories

Several large investors have recently bought and sold shares of the business. Valley National Advisers Inc. lifted its holdings in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares during the last quarter. Riverview Trust Co bought a new position in shares of IDEXX Laboratories during the 1st quarter valued at approximately $26,000. Crewe Advisors LLC purchased a new stake in IDEXX Laboratories during the 1st quarter valued at $26,000. OFI Invest Asset Management bought a new stake in IDEXX Laboratories in the third quarter worth $25,000. Finally, DSM Capital Partners LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth $33,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.